Evidence map›Paper›PMID 41050233›Full record

ArticleActa clinica Croatica2024

PROGNOSTIC VALUE OF TUMOR BUDDING IN SPORADIC COLORECTAL CANCER STAGE II PATIENTS WITH A LOW NUMBER OF LYMPH NODES EXAMINED.

Josip Baković, Čedna Tomasović-Lončarić, Arijana Pačić, Iva Škifić, Valentin Lisek, Karolina Krstanac, Petra Čičak, Paško Konjevoda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta clinica Croatica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Josip BakovićDubrava University Hospital, Department of Surgery, Zagreb, Croatia.
Čedna Tomasović-LončarićDubrava University Hospital, Department of Pathology and Cytology, Zagreb, Croatia.
Arijana PačićDubrava University Hospital, Department of Pathology and Cytology, Zagreb, Croatia.
Iva ŠkifićDubrava University Hospital, Department of Pathology and Cytology, Zagreb, Croatia.
Valentin LisekDubrava University Hospital, Department of Surgery, Zagreb, Croatia.
Karolina KrstanacDubrava University Hospital, Department of Pathology and Cytology, Zagreb, Croatia.
Petra ČičakDepartment of Emergency Medicine of the City of Zagreb, Zagreb, Croatia.
Paško KonjevodaLaboratory of Epigenomics, Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stage II colorectal cancer (CRC) is a major therapeutic challenge because it is not easy to decide whether patients will benefit from adjuvant chemotherapy or not. This study was designed as a retrospective prognostic study combining standard histopathologic parameters with tumor budding and microsatellite instability. The study included 89 patients on elective treatment for stage II primary colorectal adenocarcinoma from January 2011 to December 2015. Study results indicated that the prognosis of patients with stage II CRC depended on the combination of three factors, (in the order of importance): number of lymph nodes examined; total number of buds

Indexed as

AdenocarcinomaColorectal NeoplasmsLymph NodesAdultAgedAged, 80 and overFemaleHumansLymphatic MetastasisMaleMicrosatellite InstabilityMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisRetrospective StudiesColorectal cancerLymph nodesPrognosisStage IITumor budding

Identifiers

PMID41050233
PMCPMC12490464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.